Safety analysis
nausea, fatigue, rash, dizziness, pruritus, headache
ADVERSE EVENTS
Of the 46 patients included in the safety population that either received one or more doses of albendazole (40 patients) or were enrolled in the control group (6 patients) a total of 15 (32.6%) reported one or more adverse events at least possibly related to study drugs, including just one patient in the control group, six in the ALB group and four each in the ALB+ALB and the ALB+IVM groups. The most commonly reported at least possibly study drug related adverse events occurred within the first 3 weeks of treatment and were headache, dizziness and fatigue, followed by pruritus, rash and nausea as shown in 